- Home
- APLM vs HOTH Comparison
APLM vs HOTH Comparison
Compare APLM & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- HOTH
- Stock Information
- Founded
- APLM 2016
- HOTH 2017
- Country
- APLM United States
- HOTH United States
- Employees
- APLM N/A
- HOTH N/A
- Industry
- APLM Blank Checks
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- APLM Finance
- HOTH Health Care
- Exchange
- APLM Nasdaq
- HOTH Nasdaq
- Market Cap
- APLM 7.7M
- HOTH 8.3M
- IPO Year
- APLM N/A
- HOTH 2019
- Fundamental
- Price
- APLM $6.16
- HOTH $0.83
- Analyst Decision
- APLM Strong Buy
- HOTH Strong Buy
- Analyst Count
- APLM 2
- HOTH 3
- Target Price
- APLM $425.00
- HOTH $4.00
- AVG Volume (30 Days)
- APLM 42.6K
- HOTH 660.3K
- Earning Date
- APLM 04-15-2025
- HOTH 05-13-2025
- Dividend Yield
- APLM N/A
- HOTH N/A
- EPS Growth
- APLM N/A
- HOTH N/A
- EPS
- APLM N/A
- HOTH N/A
- Revenue
- APLM $2,101,000.00
- HOTH N/A
- Revenue This Year
- APLM N/A
- HOTH N/A
- Revenue Next Year
- APLM N/A
- HOTH N/A
- P/E Ratio
- APLM N/A
- HOTH N/A
- Revenue Growth
- APLM 70.54
- HOTH N/A
- 52 Week Low
- APLM $6.20
- HOTH $0.58
- 52 Week High
- APLM $63.00
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- APLM 42.37
- HOTH 34.96
- Support Level
- APLM $6.50
- HOTH $0.91
- Resistance Level
- APLM $8.00
- HOTH $1.05
- Average True Range (ATR)
- APLM 1.36
- HOTH 0.06
- MACD
- APLM -0.22
- HOTH -0.01
- Stochastic Oscillator
- APLM 5.93
- HOTH 0.00
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.